NEW YORK (TheStreet) -- As the most fraught influenza season since 1918 moves toward its Northern Hemisphere opening day, one outcome is perhaps more certain than any other: The hysteria surrounding the stocks of certain biotech firms will fade like summer itself.
Ever since swine flu entered the lexicon back in April, a kind of mini-bubble has developed in the shares of companies claiming to have an H1N1 fix, and that bubble seems primed to pop. More than a few developers of antiviral drugs have seen their stocks explode on little to no evidence that their treatments have any near-term commercial prospects (see: Biocryst(BCRX Quote)). But the case for the bubble's imminent deflation is even clearer among those companies attempting to develop novel influenza vaccines.![]() |
- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |















